GSK

February 5, 2012

2012 Preview: Cancer Immunotherapy Catalysts

December 14, 2011 By MD Becker Partners 1 Comment

MD Becker Partners' Life Science Digest: 2012 graphic

2012 represents a period with robust news flow for emerging immuno-oncology companies

Filed Under: Articles Tagged With: AE37, AGEN, Agenus, Allovectin, Amgen, AMGN, Antigen Express, BAVA, Bavarian Nordic, BMY, Bristol-Myers Squibb, cancer vaccine, castrate-resistant prostate cancer, CELG, Celgene, Celldex Therapeutics, CLDX, cv-301, Dendreon, DNDN, Generex, GlaxoSmithKline, GlobeImmune, GNBT, gp100, GSK, HyperAcute, Idera Pharmaceuticals, IDRA, immunotherapy, IMO-2055, ipilimumab, Jennerex, JX-594, MAGE-A3, melanoma, NewLink Genetics, NLNK, NSCLC, Oncothyreon, OncoVex, ONTY, pancreatic cancer, panvac, PROSTVAC, Provenge, QS-21, sipuleucel-T, Stimuvax, TG4010, transgene, Vical, VICL, Yervoy

Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

September 18, 2011 By MD Becker Partners Leave a Comment

MD Becker Partners' Life Science Digest: Adjuvants

Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.

Filed Under: Articles Tagged With: 3M Company, adjuvant, AE37, AGEN, Agenus, aluminum salts, Antigen Express, antigen-specific cancer immunotherapeutic, AS15, BARDA, Biomedical Advanced Research and Development Authority, BMY, Bristol-Myers Squibb, cancer immunotherapy, Cationic Lipid-DNA Complex, CDX-1401, Celldex Therapeutics, Cervarix, CLDX, Colby Pharmaceutical Company, Corixa Corporation, CpG, CyMVectin, Dendreon Corporation, DNDN, Generex Biotechnology, GLA, GlaxoSmithKline, glucopyranosyl lipid A, GNBT, GSK, Idera Pharmaceuticals, IDRA, Ii-Key hybrid technology, Immune Design Corporation, IMO-2055, ipilimumab, Juvaris BioTherapeutics, JVRS-100, MAGE-A3, MF59, MMM, monophosphoryl lipid A, Mosquirix, MPL, pandemic influenza, Provenge, QS-21, Quillaja saponaria, resiquimod, saponin, sipuleucel-T, squalene, TLR, toll-like receptor, Vaxfectin, Vical Inc., VICL, Yervoy

Cancer Immunotherapy: A Roundtable Discussion

June 30, 2011 By MD Becker Partners 3 Comments

meeting desk

Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.

Filed Under: Articles Tagged With: AGS-003, Allovectin-7, American Society of Clinical Oncology, Amgen, AMGN, AnGes, Argos Therapeutics, ASCO, AVAX Technologies, Bavarian Nordic, belagenpumatucel-L, BiovaxID, Biovest International, BLP25 liposome vaccine, BVTI, cancer immunotherapy, Cancer Research Institute, CDX-110, Celldex Therapeutics, CRI, GBM, GlaxoSmithKline, glioblastoma, GSK, Lucanix, MAGE-AS ASCI, melanoma, Merck KGA, MVA-MUC1-IL2, Novartis, Novarx, NSCLC, Oncothyreon, OncoVEX(GM-CSF), prostate cancer, PROSTVAC, rindopepimut, Stimuvax, TG4010, transgene, Vical, VICL

Ipilimumab Approval Highlights Immunotherapy Renaissance

March 25, 2011 By MD Becker Partners Leave a Comment

mab_slide

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.

Filed Under: Articles Tagged With: AGEN, Agenus, Allovectin-7, Amgen, AMGN, Antigenics, AVAX, AVAX Technologies, AVXT.PK, Bavarian Nordic, BIIB, Biogen Idec, BiovaxID, Biovest International, BioVex, BMY, Bristol-Myers Squibb, BVTI, CancerVax, Canvaxin, CDX-110, Celldex Therapeutics, CLDX, Corixa, Dendreon, DNDN, GlaxoSmithKline plc, GMK vaccine, GSK, ipilimumab, Lucanix, MAGE-A3 ASCI, Melacine, MVAX, Novarx, Oncophage, Oncothyreon, OncoVex, ONTY, Oxford BioMedica, PGNX, Progenics Pharmaceuticals, PROSTVAC, Rituxan, rituximab, Stimuvax, TG4010, transgene, Trovax, Vical, VICL, William Coley, Yervoy

FDA Advisory Panels: No Means No, Yes Means Maybe

February 6, 2011 By MD Becker Partners 3 Comments

MD Becker Partners' Life Science Digest: FDA Advisory Panels - No Means No, Yes Means Maybe

As the only company to receive a positive United States Food and Drug Administration [FDA] Advisory Committee [AdCom] recommendation for a product candidate to treat obesity in 2010, Orexigen Therapeutics, Inc. (OREX) appeared well positioned to receive marketing approval for Contrave® [naltrexone HCl/bupropion HCI]. However, on January 31, 2011, Orexigen and its partner Takeda Pharmaceutical [...]

Filed Under: Articles Tagged With: ACUR, Acura Pharmaceuticals, Acurox, Advisory Committee, Alkermes, ALKS, AstraZeneca plc, AZN, Bayer AG, BAYRY.PK, Belatacept, belimumab, Benlysta, Boehringer Ingelheim, Bristol-Myers Squibb, Cell Therapeutics, ChemGenex Pharmaceuticals, Complete Response Letter, Contrave, CRL, CTIC, dabigatran etexilate, Dendreon Corporation, DNDN, Eli Lilly & Co, EsBriet, ezogabine, FDA, Flibanserin, Gadobutrol, GlaxoSmithKline plc, GSK, HGSI, Horizon Pharma, HRA Pharma, Human Genome Sciences, HZT-501, InterMune, ITMN, JAZZ, Jazz Pharmaceuticals, KG, King Pharmaceuticals, liprotamase, LLY, MELA, MELA Sciences, MelaFind, Motavizumab, naltrexone/bupropion, Naproxcinod, Oceana Therapeutics, omacetaxine mepesuccinate, OREX, Orexigen Therapeutics, oxycodone HCl, pirfenidone, pixantrone dimaleate, Provenge, sipuleucil-T, Solesta, Takeda Pharmaceutical Company, tesamorelin acetate, Theratechnologies, Ticagrelor, ulipristal acetate, Valeant Pharmaceuticals International, Vandetanib, VRX